Date: 2012-06-19
Type of information: Licensing agreement
Compound: multiplex gene expression assay SeptiCyte® Triage
Company: Biocartis (Belgium) Debiopharm (Switzerland) Immunexpress (Australia)
Therapeutic area: Infectious diseases
Type agreement: licensing
development
commercialisation
Action mechanism: The Immunexpress SeptiCyte® technology quantifies specific and multiple molecular markers from the patient’s own immune system for earlier detection, severity assessment, and better timing and targeting of drug and other therapies. Results from Immunexpress clinical trials show that biomarkers of the patient’s immune response are more accurate and instructive than pathogen detection for early detection and improved management of sepsis. By translating and quantifying complex molecular signals in an objective score, SeptiCyte® technology provides reports on disease probabilities – enabling clinicians to better manage sepsis patients for improved patient outcomes. The SeptiCyte® technology is the basis for three products – SeptiCyte® Triage, SeptiCyte® STAT, and SeptiCyte® RTT – which are intended for use on the Biocartis platform in a variety of critical care hospital settings, but will also be available for other standard hospital laboratory platforms.
Disease: sepsis
Details: The molecular diagnostic companies Immunexpress and Biocartis and the Swiss-based biopharmaceutical company Debiopharm have announced a worldwide exclusive, royalty-bearing license for the late-stage development and commercialization of SeptiCyte® Triage – a multiplex gene expression assay for use in Emergency and Intensive Care Units (ICUs) or upon hospital admission to diagnose sepsis early, differentiate sepsis from other forms of inflammation, and determine sepsis severity.
Financial terms: Under the terms of the agreement, Debiopharm will fund the validation and FDA clearance of SeptiCyte® Triage and Biocartis will subsequently fund the development and commercialization of the validated SeptiCyte® Triage assay on its fully integrated molecular diagnostics platform. As part of the agreement, Debiopharm will complete an equity investment in Immunexpress of AUD 2 million.
Latest news:
